
EU Pharma Industry Representatives Pen Letter on Brexit
Members of ABPI, GSK, AstraZeneca, and the BioIndustry Association composed a letter explaining why the UK remaining part of the EU benefits the life-sciences sector.
Members of the Association of British Pharmaceutical Industries (ABPI), GlaxoSmithKline (GSK), AstraZeneca, and the BioIndustry Association expressed their opinion on the upcoming European Union (EU) referendum in a
The highly anticipated
“We see significant advantages for the life-sciences sector in the UK remaining part of the EU,” the industry representatives wrote in the Observer. “This would enable the sector to continue to operate within an established and harmonized regulatory approval system, ensuring that UK patients benefit from medicines more quickly, and that medicines researched and manufactured in the UK are available across the EU sooner.”
Remaining part of the EU might also benefit pharmaceutical companies when it comes to issues of international trade, the writers assert. Leaving the EU, they say, “would bring added complexity and uncertainty, which is bad for business and research.” The life-sciences industry in the UK has grown to £60.7 billion (approximately $87.76 billion), according to BIS. The sector includes 222,000 employees across the UK, spending £4 billion (approximately $5.78 billion) on R&D, industry representatives noted in the Observer.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.